Works by Siddiqi, T.

Results: 35

Patients' satisfaction and opinions of their experiences duringadmission in a tertiary care hospital in Pakistan -- a cross sectionalstudy.

Published in:

BMC Health Services Research, 2007, v. 7, p. 161, doi. 10.1186/1472-6963-7-161

By:

Imam, Sardar Zakariya;
Syed, Khezar Shahzada;
Ali, Syed Ahad;
Ali, Syed Umer;
Fatima, Kiran;
Gill, Marium;
Hassan, Muhammad Ovais;
Hashmi, Saad Hasan;
Siddiqi, Maham T.;
Khan, Hadi Muhammad;
Jameel, Omar Farooq

Publication type:

Article

PB1878: CROSS‐TRIAL ANALYSIS OF FIXED‐DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST‐LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Published in:

HemaSphere, 2022, v. 6, p. 1758, doi. 10.1097/01.HS9.0000850364.78915.d9

By:

Barrientos, J. C.;
Barr, P. M.;
Mato, A. R.;
Tam, C. S.;
Ghia, P.;
Moreno, C.;
Kay, N. E.;
Siddiqi, T.;
Szafer‐Glusman, E.;
Zhou, C.;
Neumayr, L.;
Krigsfeld, G.;
Wierda, W. G.;
Shanafelt, T.

Publication type:

Article

P669: FIXED‐DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3‐YEAR FOLLOW‐UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT.

Published in:

HemaSphere, 2022, v. 6, p. 567, doi. 10.1097/01.HS9.0000845560.07338.2d

By:

Moreno, C.;
Wierda, W. G.;
Barr, P. M.;
Siddiqi, T.;
Allan, J. N.;
Kipps, T. J.;
Trentin, L.;
Jacobs, R.;
Jackson, S.;
Tedeschi, A.;
Opat, S.;
Bannerji, R.;
Kuss, B. J.;
Croner, L. J.;
Szafer‐Glusman, E.;
Zhou, C.;
Szoke, A.;
Dean, J. P.;
Ghia, P.;
Tam, C. S.

Publication type:

Article

P667: LONG‐TERM EFFICACY OF ACALABRUTINIB‐BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND HIGHER‐RISK GENOMIC FEATURES: POOLED ANALYSIS OF CLINICAL TRIAL DATA.

Published in:

HemaSphere, 2022, v. 6, p. 565, doi. 10.1097/01.HS9.0000845552.95839.3f

By:

Davids, M.;
Sharman, J.;
Ghia, P.;
Woyach, J.;
Jurczak, W.;
Siddiqi, T.;
Miranda, P.;
Shahkarami, M.;
Yu, T.;
Emeribe, U.;
Byrd, J.

Publication type:

Article

Deficient counterregulation: a possible risk factor for excessive fetal growth in IDDM pregnancies.

Published in:

1997

By:

Rosenn, Barak M.;
Miodovnik, Menachem;
Khoury, Jane C.;
Siddiqi, Tariq A.;
Rosenn, B M;
Miodovnik, M;
Khoury, J C;
Siddiqi, T A

Publication type:

journal article

Landmark Publications on Sudden Infant Death Syndrome: A Bibliometric Analysis.

Published in:

Forensic Science Review, 2020, v. 32, n. 2, p. 117

By:

Menezes, R. G.;
Usman, M. S.;
Memon, M. M.;
Siddiqi, T. J.;
Madadin, M.

Publication type:

Article

Landmark Publications on Sudden Infant Death Syndrome: A Bibliometric Analysis.

Published in:

Forensic Science Review, 2020, v. 32, n. 2, p. 117

By:

Menezes, R. G.;
Usman, M. S.;
Memon, M. M.;
Siddiqi, T. J.;
Madadin, M.

Publication type:

Article

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R MCL: PRIMARY ANALYSIS RESULTS FROM THE MCL COHORT OF THE SINGLE‐ARM, MULTICENTER, SEAMLESS DESIGN TRANSCEND NHL 001 STUDY.

Published in:

Hematological Oncology, 2023, v. 41, p. 875, doi. 10.1002/hon.3196_LBA3

By:

Wang, M.;
Siddiqi, T.;
Gordon, L. I.;
Kamdar, M.;
Lunning, M.;
Hirayama, A. V.;
Abramson, J. S.;
Arnason, J.;
Ghosh, N.;
Mehta, A.;
Andreadis, C.;
Solomon, S. R.;
Kostic, A.;
Dehner, C.;
Espinola, R.;
Peng, L.;
Ogasawara, K.;
Chattin, A.;
Palomba, M. L.

Publication type:

Article

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL).

Published in:

Hematological Oncology, 2023, v. 41, p. 587, doi. 10.1002/hon.3164_440

By:

Lee, H.;
Choi, M.;
Siddiqi, T.;
Rhodes, J.;
Wierda, W.;
Isufi, I.;
Tuscano, J.;
Lamanna, N.;
Subbiah, S.;
Koff, J.;
Leslie, L.;
Goldenberg, A.;
Chung, G.;
Breitmeyer, J.;
Yazji, S.;
Shih, T.;
Wang, M.;
Jamieson, C.;
Kipps, T.

Publication type:

Article

Health‐related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso‐cel in TRANSCEND CLL 004.

Published in:

Hematological Oncology, 2023, v. 41, p. 538, doi. 10.1002/hon.3164_400

By:

Maloney, D. G.;
Siddiqi, T.;
Fakhri, B.;
Ma, S.;
Shah, N. N.;
Riedell, P. A.;
Schuster, S. J.;
Eliason, L.;
Wang, L.;
Tuazon, S. A.;
Ou, S.;
Shi, L.;
Ye, X.;
Kenderian, S. S.

Publication type:

Article

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): PRIMARY ANALYSIS OF TRANSCEND CLL 004.

Published in:

Hematological Oncology, 2023, v. 41, p. 60, doi. 10.1002/hon.3163_26

By:

Siddiqi, T.;
Maloney, D. G.;
Kenderian, S. S.;
Brander, D. M.;
Dorritie, K.;
Soumerai, J.;
Riedell, P. A.;
Shah, N. N.;
Nath, R.;
Fakhri, B.;
Stephens, D. M.;
Ma, S.;
Feldman, T.;
Solomon, S. R.;
Schuster, S. J.;
Perna, S. K.;
Tuazon, S.;
Ou, S.;
Papp, E.;
Chen, Y.

Publication type:

Article

FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY.

Published in:

Hematological Oncology, 2023, v. 41, p. 238, doi. 10.1002/hon.3163_155

By:

Ghia, P.;
Allan, J. N.;
Siddiqi, T.;
Wierda, W. G.;
Tam, C. S.;
Moreno, C.;
Tedeschi, A.;
Szafer‐Glusman, E.;
Zhou, C.;
Abbazio, C.;
Dean, J. P.;
Szoke, A.;
Barr, P. M.

Publication type:

Article

TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL.

Published in:

Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.86_2879

By:

Wierda, W. G.;
Dorritie, K. A.;
Munoz, J.;
Stephens, D. M.;
Solomon, S.;
Gillenwater, H. H.;
Gong, L.;
Yang, L.;
Ogasawara, K.;
Thorpe, J.;
Siddiqi, T.

Publication type:

Article

CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Published in:

Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.32_2879

By:

Tam, C. S. L;
Allan, J. N;
Siddiqi, T;
Kipps, T. J;
Jacobs, R;
Opat, S;
Barr, P. M;
Tedeschi, A;
Trentin, L;
Bannerji, R;
Jackson, S;
Kuss, B;
Moreno, C;
Szafer‐Glusman, E;
Russell, K;
Zhou, C;
Ninomoto, J;
Dean, J. P;
Ghia, P;
Wierda, W. G

Publication type:

Article

TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA.

Published in:

Hematological Oncology, 2019, v. 37, p. 109, doi. 10.1002/hon.71_2629

By:

Siddiqi, T.;
Dorritie, K.A.;
Soumerai, J.D.;
Stephens, D.M.;
Dubovsky, J.A.;
Gillenwater, H.H.;
Gong, L.;
Thorpe, J.;
Yang, L.;
Wierda, W.G.

Publication type:

Article

MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR‐T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMA.

Published in:

Hematological Oncology, 2019, v. 37, p. 507, doi. 10.1002/hon.190_2631

By:

Shouse, G.P.;
Xue, T.;
Herrera, A.;
Siddiqi, T.;
Zain, J.;
Popplewell, L.;
Forman, S.;
Budde, E.

Publication type:

Article

SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B‐CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY.

Published in:

Hematological Oncology, 2019, v. 37, p. 171, doi. 10.1002/hon.128_2629

By:

Siddiqi, T.;
Abramson, J.S.;
Lee, H.J.;
Schuster, S.;
Hasskarl, J.;
Montheard, S.;
Dell Aringa, J.;
Thompson, E.;
Ananthakrishnan, R.;
Lunning, M.

Publication type:

Article

SAFETY AND PRELIMINARY EFFICACY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL IN TRANSCEND NHL 001.

Published in:

Hematological Oncology, 2019, v. 37, p. 301, doi. 10.1002/hon.111_2630

By:

Wang, M.;
Gordon, L.I.;
Palomba, M.L.;
Abramson, J.S.;
Andreadis, C.;
Ghosh, N.;
Lunning, M.;
Maloney, D.;
Farazi, T.;
Garcia, J.;
Xie, B.;
Newhall, K.;
Dehner, C.;
Siddiqi, T.

Publication type:

Article

TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA.

Published in:

Hematological Oncology, 2019, v. 37, p. 109, doi. 10.1002/hon.71_2629

By:

Siddiqi, T.;
Dorritie, K.A.;
Soumerai, J.D.;
Stephens, D.M.;
Dubovsky, J.A.;
Gillenwater, H.H.;
Gong, L.;
Thorpe, J.;
Yang, L.;
Wierda, W.G.

Publication type:

Article

MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR‐T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMA.

Published in:

Hematological Oncology, 2019, v. 37, p. 507, doi. 10.1002/hon.190_2631

By:

Shouse, G.P.;
Xue, T.;
Herrera, A.;
Siddiqi, T.;
Zain, J.;
Popplewell, L.;
Forman, S.;
Budde, E.

Publication type:

Article

SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B‐CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY.

Published in:

Hematological Oncology, 2019, v. 37, p. 171, doi. 10.1002/hon.128_2629

By:

Siddiqi, T.;
Abramson, J.S.;
Lee, H.J.;
Schuster, S.;
Hasskarl, J.;
Montheard, S.;
Dell Aringa, J.;
Thompson, E.;
Ananthakrishnan, R.;
Lunning, M.

Publication type:

Article

SAFETY AND PRELIMINARY EFFICACY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RECEIVING LISOCABTAGENE MARALEUCEL IN TRANSCEND NHL 001.

Published in:

Hematological Oncology, 2019, v. 37, p. 301, doi. 10.1002/hon.111_2630

By:

Wang, M.;
Gordon, L.I.;
Palomba, M.L.;
Abramson, J.S.;
Andreadis, C.;
Ghosh, N.;
Lunning, M.;
Maloney, D.;
Farazi, T.;
Garcia, J.;
Xie, B.;
Newhall, K.;
Dehner, C.;
Siddiqi, T.

Publication type:

Article

AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT-NAÏVE CLL/SLL.

Published in:

Hematological Oncology, 2017, v. 35, p. 428, doi. 10.1002/hon.2440_13

By:

Ghia, P.;
Tam, C.S.;
Siddiqi, T.;
Stevens, D.;
Flinn, I.W.;
Russell, K.;
Eckert, K.;
Zhou, C.;
Ninomoto, J.;
James, D.F.;
Wierda, W.G.

Publication type:

Article

PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL).

Published in:

Hematological Oncology, 2017, v. 35, p. 262, doi. 10.1002/hon.2438_132

By:

Neelapu, S.S.;
Rossi, J.M.;
Locke, F.L.;
Xue, A.;
Better, M.;
Zhang, X.;
Ghobadi, A.;
Lekakis, L.J.;
Miklos, D.;
Jacobson, C.A.;
Braunschweig, I.;
Oluwole, O.;
Siddiqi, T.;
Lin, Y.;
Timmerman, J.;
Reagan, P.M.;
Navale, L.;
Go, W.Y.;
Wiezorek, J.;
Bot, A.

Publication type:

Article

COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA.

Published in:

Hematological Oncology, 2017, v. 35, p. 266, doi. 10.1002/hon.2438_137

By:

Lunning, M.A.;
Vose, J.M.;
Bierman, P.J.;
Bociek, G.;
Schreeder, M.T.;
Siddiqi, T.;
Blumel, S.M.;
Cutter, K.;
Pauli, E.K.;
Bui, D.;
Sportelli, P.;
Miskin, H.P.;
Purdom, M.;
Weiss, M.S.;
Fowler, N.H.

Publication type:

Article

CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL.

Published in:

Hematological Oncology, 2017, v. 35, p. 112, doi. 10.1002/hon.2437_101

By:

Nastoupil, L.;
Lunning, M.A.;
Vose, J.M.;
Schreeder, M.T.;
Siddiqi, T.;
Flowers, C.R.;
Cohen, J.B.;
Burger, J.A.;
Wierda, W.G.;
O'Brien, S.;
Sportelli, P.;
Miskin, H.P.;
Purdom, M.A.;
Weiss, M.S.;
Fowler, N.H.

Publication type:

Article

HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001).

Published in:

Hematological Oncology, 2017, v. 35, p. 138, doi. 10.1002/hon.2437_127

By:

Abramson, J.;
Palomba, M.L.;
Gordon, L.;
Lunning, M.;
Arnason, J.;
Wang, M.;
Forero ‐ Torres, A.;
Albertson, T.;
Allen, T.;
Sutherland, C.;
Xie, B.;
Garcia, J.;
Siddiqi, T.

Publication type:

Article

AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1.

Published in:

Hematological Oncology, 2017, v. 35, p. 28, doi. 10.1002/hon.2437_7

By:

Neelapu, S.S.;
Locke, F.L.;
Bartlett, N.L.;
Lekakis, L.J.;
Miklos, D.;
Jacobson, C.A.;
Braunschweig, I.;
Oluwole, O.;
Siddiqi, T.;
Lin, Y.;
Timmerman, J.;
Reagan, P.;
Navale, L.;
Jiang, Y.;
Aycock, J.;
Elias, M.;
Wiezorek, J.;
Go, W.Y.

Publication type:

Article

Enhancement in furanocoumarin content and phenylalanine ammonia lyase activity in developing seedlings of Psoralea corylifolia L. in response to gamma irradiation of seeds.

Published in:

Radiation & Environmental Biophysics, 2012, v. 51, n. 3, p. 341, doi. 10.1007/s00411-012-0421-1

By:

Jan, Sumira;
Parween, Talat;
Siddiqi, T.;
Mahmooduzzafar

Publication type:

Article

Restructuring BOD : COD ratio of dairy milk industrial wastewaters in BOD analysis by formulating a specific microbial seed.

Published in:

2012

By:

Dhall, Purnima;
Siddiqi, T O;
Ahmad, Altaf;
Kumar, Rita;
Kumar, Anil

Publication type:

journal article

Restructuring BOD: COD Ratio of Dairy Milk Industrial Wastewaters in BOD Analysis by Formulating a Specific Microbial Seed.

Published in:

Scientific World Journal, 2012, p. 1, doi. 10.1100/2012/105712

By:

Dhall, Purnima;
Siddiqi, T. O.;
Ahmad, Altaf;
Kumar, Rita;
Kumar, Anil

Publication type:

Article

Perceptions of Pakistani medical students about drugs and alcohol: a questionnaire-based survey.

Published in:

Substance Abuse Treatment, Prevention & Policy, 2006, v. 1, p. 31, doi. 10.1186/1747-597X-1-31

By:

Shafiq, Majid;
Shah, Zaman;
Saleem, Ayesha;
Siddiqi, Maham T.;
Shaikh, Kashif S.;
Salahuddin, Farah F.;
Siwani, Rizwan;
Naqvi, Haider

Publication type:

Article

Major malformations in infants of IDDM women. Vasculopathy and early first-trimester poor glycemic control.

Published in:

1988

By:

Miodovnik, M;
Mimouni, F;
Dignan, P S;
Berk, M A;
Ballard, J L;
Siddiqi, T A;
Khoury, J;
Tsang, R C

Publication type:

journal article

Gamma radiation effects on growth and yield attributes of Psoralea corylifolia L. with reference to enhanced production of psoralen.

Published in:

Plant Growth Regulation, 2011, v. 64, n. 2, p. 163, doi. 10.1007/s10725-010-9552-z

By:

Jan, Sumira;
Parween, Talat;
Siddiqi, T. O.;
Mahmooduzzafar

Publication type:

Article

A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin and rituximab.

Published in:

2008

By:

Siddiqi T;
Joyce RM

Publication type:

Journal Article